National Institutes of Health, a Component of the US Dept. of Health & Human Services

US Government As Represented by the Secretary of the Army

Thomas Jefferson University

The Walter Reed Army Institute of Research

Joseph E Blaney

Stephen Whitehead

Brian R Murphy

Ching-Juh Lai

Kathryn A Hanley

Lewis Markoff

Barry Falgout

Robert M Chanock

Joseph R Putnak

Alexander G Pletnev

Matthias Johannes Schnell

Peter B Jahrling

Reed F Johnson

Jason Paragas

Stephen S Whitehead

Mathias Schnell

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3' untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

Development of dengue virus vaccine components

The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (&#x394;30) in the 3'-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3' untranslated region (3&#x2032;-UTR) comprising a &#x394;30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the &#x394;30 mutation deleted from the 3&#x2032;-UTR that removes sequence in the 5&#x2032; direction as far as the 5&#x2032; boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3&#x2032;-UTR of a dengue virus of a first serotype with the 3&#x2032;-UTR of a dengue virus of a second serotype, optionally containing the &#x394;30 mutation and nucleotides additional to the &#x394;30 mutation deleted from the 3&#x2032;-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,

Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.

Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.

The present invention provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a filovirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a filovirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present invention provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one filovirus glycoprotein or an immunogenic fragment thereof, as well as pharmaceutical compositions comprising the vaccine vectors.

Multivalent vaccines for rabies virus and filoviruses

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4

Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3' untranslated region (3&#x2032;-UTR) comprising a &#x394;30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the &#x394;30 mutation deleted from the 3&#x2032;-UTR that removes sequence in the 5&#x2032; direction as far as the 5&#x2032; boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3&#x2032;-UTR of a dengue virus of a first serotype with the 3&#x2032;-UTR of a dengue virus of a second serotype, optionally containing the &#x394;30 mutation and nucleotides additional to the &#x394;30 mutation deleted from the 3&#x2032;-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

Growing community of inventors

Gettysburg, PA, United States of America

Joseph E Blaney